ATE200222T1 - Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten - Google Patents

Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten

Info

Publication number
ATE200222T1
ATE200222T1 AT93903433T AT93903433T ATE200222T1 AT E200222 T1 ATE200222 T1 AT E200222T1 AT 93903433 T AT93903433 T AT 93903433T AT 93903433 T AT93903433 T AT 93903433T AT E200222 T1 ATE200222 T1 AT E200222T1
Authority
AT
Austria
Prior art keywords
carbon atoms
independently selected
mammal
alkyl radicals
group
Prior art date
Application number
AT93903433T
Other languages
English (en)
Inventor
Charles Gluchowski
Michael E Garst
James A Burke
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE200222T1 publication Critical patent/ATE200222T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT93903433T 1992-01-13 1993-01-12 Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten ATE200222T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/820,329 US5231096A (en) 1989-10-12 1992-01-13 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
PCT/US1993/000264 WO1993013771A1 (en) 1992-01-13 1993-01-12 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Publications (1)

Publication Number Publication Date
ATE200222T1 true ATE200222T1 (de) 2001-04-15

Family

ID=25230500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93903433T ATE200222T1 (de) 1992-01-13 1993-01-12 Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten

Country Status (9)

Country Link
US (1) US5231096A (de)
EP (1) EP0620732B1 (de)
JP (1) JPH07503015A (de)
AT (1) ATE200222T1 (de)
AU (1) AU670064B2 (de)
CA (1) CA2127542C (de)
DE (1) DE69330090T2 (de)
ES (1) ES2157216T3 (de)
WO (1) WO1993013771A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
EP1285657A3 (de) * 1993-10-13 2003-08-20 Allergan, Inc. Verfahren zur Verwendung von (2-imidazolin-2-yl-amino) Quinoxalinderivaten
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
CN1046718C (zh) * 1993-12-17 1999-11-24 普罗克特和甘保尔公司 用作α－2肾上腺素能受体兴奋剂的6－(2－亚咪唑烷基氨基)喹啉化合物
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CA2179006A1 (en) * 1993-12-17 1995-06-22 Peter Julian Maurer 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
ATE153330T1 (de) * 1994-02-08 1997-06-15 Alcon Lab Inc Neues verfahren zur herstellung von clonidin- derivaten
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
JP2001524478A (ja) 1997-11-24 2001-12-04 ザ プロクター アンド ギャンブル カンパニー ５−（２−イミダゾリニルアミノ）−ベンゾイミダゾール誘導体類、それらの調製および改良された代謝安定性を有するアルファアドレナリン受容体作動薬としてのそれらの使用
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
DK1654002T4 (da) * 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
EP1956906A4 (de) 2005-11-09 2009-12-30 Combinatorx Inc Verfahren, zusammensetzungen und kits für die behandlung von medizinischen beschwerden

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Also Published As

Publication number Publication date
JPH07503015A (ja) 1995-03-30
US5231096A (en) 1993-07-27
ES2157216T3 (es) 2001-08-16
EP0620732A1 (de) 1994-10-26
CA2127542C (en) 2004-08-03
CA2127542A1 (en) 1993-07-22
AU3470093A (en) 1993-08-03
DE69330090D1 (de) 2001-05-10
EP0620732B1 (de) 2001-04-04
DE69330090T2 (de) 2001-09-20
AU670064B2 (en) 1996-07-04
WO1993013771A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
CA2173974A1 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ATE200222T1 (de) Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten
ATE104973T1 (de) (2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren.
EP0549594A4 (de) (2-imidazolin-2-ylamino)chinoxalinderivate und methoden in ihrer anwendung.
KR940014328A (ko) 인돌린 화합물
NO152902C (no) Analogifremgangsmaae for fremstilling av terapeutisk virksomme 1-alkyl-2-aminotetralinderivater
ATE198046T1 (de) Neue hemmer von uridinphosphorylase (urdpase) und dihydrouracildehydrogenase (dhudase)
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
NO923413L (no) Terapeutiske benzazepin-forbindelser
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
KR960703912A (ko) 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity)
LU90791I2 (fr) Potentialisateur d'effets antineoplasique et agent antineoplasique
ATE131055T1 (de) Behandlung von kognitiven störungen.
NO923198L (no) Terapeutiske midler
MY108455A (en) Therapeutic benzazapine compounds.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties